-
Why Galectin Therapeutics Just Lost Nearly Half Its Market Cap
Wednesday, September 28, 2016 - 10:59am | 352Read More...Shares of Galectin Therapeutics Inc (NASDAQ: GALT), a clinical-stage biopharmaceutical company that creates therapies for fibrotic disease and cancer, tumbled nearly 50 percent on Wednesday after the company said that a Phase 2a study called NASH-FX involving its GR-MD-02 therapy failed its...
-
Market Wrap For January 10: Job Growth Weak, But Unemployment Falls
Friday, January 10, 2014 - 5:53pm | 2337Read More...Major indices ended the day little changed as investors and traders were not sure how to react to today's job reports. 74,000 jobs were added, well below the estimated 196,000. The report proved to be a complete contradiction to every other report previously seen. Related: ETFs Moving On The...
